Recruiting INTERVENTIONAL NCT06857955

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

A Randomized, Double-blind, Placebo-controlled, Multicenter, 12 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients

Sponsor: Novartis Pharmaceuticals

Conditions Hypertension

Interventions QCZ484 Saline

Updated 8 times since 2025 Last updated: Apr 24, 2026 Started: Mar 26, 2025 Primary completion: Jan 29, 2027 Completion: Apr 5, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypertension and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Study Description(click to expand)

Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of QCZ484 with mild to moderate hypertension (HTN). Multiple doses of QCZ484 will be tested against placebo, administered as subcutaneous injection.

Status Flow

Change History

8 versions recorded

May 4, 2026 — Present [daily]

Recruiting

Phase: PHASE2 → None
Feb 2026 — May 2026 [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Sep 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Mar 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Andalusia, United States , Austin, United States , Baltimore, United States , Baton Rouge, United States , Bedford, United States , Berlin, United States , Binghamton, United States , Birmingham, United States , Brandon, United States , Charlotte, United States and 74 more locations